Entry
Name
Alefacept (USAN/INN); Amevive (TN)
Formula
C3264H5002N840O988S20
Exact mass
72414.1400
Mol weight
72459.00
Sequence
FSQQIYGVVY GNVTFHVPSN VPLKEVLWKK QKDKVAELEN SEFRAFSSFK NRVYLDTVSG SLTIYNLTSS DEDEYEMESP NITDTMKFFL YVDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK (Disulfide bridge: 98-98', 101-101', 133-193, 239-297, 133'-193', 239'-297')
Type
Peptide
Remark
Efficacy
Antipsoriatic, Immunosuppressant
Comment
Alefacept is a fusion protein combining the first extracellular domain of LFA3 [HSA:
965 ] [KO:
K06492 ] with constant regions, CH2 and CH3.
LFA-3Ig
Treatment of plaque psoriasis
Target
Pathway
Interaction
DDI search
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303 ]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AA Selective immunosuppressants
L04AA15 Alefacept
D02800 Alefacept (USAN/INN)
Target-based classification of drugs [BR:br08310 ]
Cell surface molecules and ligands
Cell adhesion molecules: Ig superfamiy
CD2 family
CD58 (LFA3)
D02800 Alefacept (USAN/INN)
BRITE hierarchy
Other DBs